Phenylephrine
Active ingredient: Phenylephrine Hydrochloride
In short: Phenylephrine hydrochloride injection, 10 mg/mL is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.
What is Phenylephrine used for?
Phenylephrine hydrochloride injection, 10 mg/mL is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.
Phenylephrine dosage
2.1 General Dosage and Administration Instructions
Phenylephrine hydrochloride injection, 10 mg/mL must be diluted before administration as an intravenous bolus or continuous intravenous infusion to achieve the desired concentration:
Bolus: Dilute with normal saline or 5% dextrose in water.
Continuous infusion: Dilute with normal saline or 5% dextrose in water.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if the solution is colored or cloudy, or if it contains particulate matter. The diluted solution should not be held for more than 4 hours at room temperature or for more than 24 hours under refrigerated conditions. Discard any unused portion.
During phenylephrine hydrochloride injection administration:
Correct intravascular volume depletion.
Correct acidosis. Acidosis may reduce the effectiveness of phenylephrine.
2.2 Dosing for Treatment of Hypotension during Anesthesia
The following are the recommended dosages for the treatment of hypotension during anesthesia.
The recommended initial dose is 40 mcg to 100 mcg administered by intravenous bolus. Additional boluses may be administered every 1 to 2 minutes as needed; not to exceed a total dosage of 200 mcg.
If blood pressure is below the target goal, start a continuous intravenous infusion with an infusion rate of 10 to 35 mcg/minute; not to exceed 200 mcg/minute.
Adjust dosage according to the blood pressure goal.
2.3 Prepare a 100 mcg/mL Solution for Bolus Intravenous Administration
For bolus intravenous administration, prepare a solution containing a final concentration of 100 mcg/mL of phenylephrine hydrochloride injection:
Withdraw 10 mg (1 mL of 10 mg/mL) of phenylephrine hydrochloride and dilute with 99 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP.
Withdraw an appropriate dose from the 100 mcg/mL solution prior to bolus intravenous administration.
2.4 Prepare a Solution for Continuous Intravenous Administration
For continuous intravenous infusion, prepare a solution containing a final concentration of 20 mcg/mL of phenylephrine hydrochloride in 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP:
Withdraw 10 mg (1 mL of 10 mg/mL) of phenylephrine hydrochloride and dilute with 500 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP.
How to take Phenylephrine — instructions & advice from the label
If applicable, inform patient, family member, or caregiver that certain medical conditions and medications might influence how phenylephrine hydrochloride injection works.
Manufactured by:
Amneal Pharmaceuticals Pvt. Ltd.
Ahmedabad 382213, INDIA
Or
Amneal Pharmaceuticals Pvt. Ltd.
Parenteral UnitAhmedabad 382110, INDIA
Or
Amneal Pharmaceuticals Pvt. Ltd.
Mehsana 382165, INDIA
Distributed by:
Amneal Pharmaceuticals LLC
Bridgewater, NJ 08807
Rev. 07-2024-05
Warnings & precautions
Do not take this medicine if: None
5.1 Exacerbation of Angina, Heart Failure, or Pulmonary Arterial Hypertension
Because of its increasing blood pressure effects, phenylephrine hydrochloride can precipitate angina in patients with severe arteriosclerosis or history of angina, exacerbate underlying heart failure, and increase pulmonary arterial pressure.
5.2 Peripheral and Visceral Ischemia
Phenylephrine hydrochloride can cause excessive peripheral and visceral vasoconstriction and ischemia to vital organs, particularly in patients with extensive peripheral vascular disease.
5.3 Skin and Subcutaneous Necrosis
Extravasation of phenylephrine hydrochloride can cause necrosis or sloughing of tissue. The infusion site should be checked for free flow. Care should be taken to avoid extravasation of phenylephrine hydrochloride.
5.4 Bradycardia
Phenylephrine hydrochloride can cause severe bradycardia and decreased cardiac output.
5.5 Allergic Reactions
Phenylephrine hydrochloride injection contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
5.6 Renal Toxicity
Phenylephrine hydrochloride can increase the need for renal replacement therapy in patients with septic shock. Monitor renal function.
5.7 Risk of Augmented Pressor Affect in Patients with Autonomic Dysfunction
The increasing blood pressure response to adrenergic drugs, including phenylephrine hydrochloride, can be increased in patients with autonomic dysfunction, as may occur with spinal cord injuries. …
Phenylephrine side effects
Adverse reactions to phenylephrine hydrochloride are primarily attributable to excessive pharmacologic activity. Adverse reactions reported in published clinical studies, observational trials, and case reports of phenylephrine hydrochloride are listed below by body system. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.
Cardiac disorders: Reflex bradycardia, lowered cardiac output, ischemia, hypertension, arrhythmias
Gastrointestinal disorders: Epigastric pain, vomiting, nausea
Nervous system disorders: Headache, blurred vision, neck pain, tremors
Vascular disorders: Hypertensive crisis
Respiratory, Thoracic and Mediastinal Disorders: Dyspnea
Skin and subcutaneous tissue disorders: Pruritis
Drug interactions
7.1 Interactions that Augment Pressor Effect
The increasing blood pressure effect of phenylephrine hydrochloride is increased in patients receiving:
Monoamine oxidase inhibitors (MAOI)
Oxytocin and oxytocic drugs
Tricyclic antidepressants
Angiotensin, aldosterone
Atropine
Steroids, such as hydrocortisone
Norepinephrine transporter inhibitors, such as atomoxetine
Ergot alkaloids, such as methylergonovine maleate
7.2 Interactions that Antagonize the Pressor Effect
The increasing blood pressure effect of phenylephrine hydrochloride is decreased in patients receiving:
α-adrenergic antagonists
Phosphodiesterase Type 5 inhibitors
Mixed α- and β-receptor antagonists
Calcium channel blockers, such as nifedipine
Benzodiazepines
ACE inhibitors
Centrally acting sympatholytic agents, such as reserpine, guanfacine
About this medicine
Phenylephrine is an alpha-1 adrenergic receptor agonist. Phenylephrine hydrochloride injection USP, 10 mg/mL, is a clear, colorless, sterile, nonpyrogenic solution for intravenous use. It must be diluted before administration as an intravenous bolus or continuous intravenous infusion. The chemical name of phenylephrine hydrochloride is (-)-m-hydroxy-α-[(methylamino)methyl]benzyl alcohol hydrochloride, and its structural formula is depicted below:
Phenylephrine hydrochloride, USP is a white or practically white crystals with a molecular formula of C9H13NO2 • HCl and a molecular weight of 203.67. It is freely soluble in water and in alcohol.
Phenylephrine hydrochloride injection USP, 10 mg/mL is sensitive to light.
Each mL contains: phenylephrine hydrochloride, USP 10 mg, sodium chloride 3.5 mg, trisodium citrate dihydrate 4 mg, citric acid monohydrate 1 mg, and sodium metabisulfite 2 mg in water for injection. The pH is adjusted with sodium hydroxide and/or hydrochloric acid if necessary. The pH range is 3.5 to 5.5. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID db313f72-a6bb-444f-949f-19b4aa6f61c0. Read the full official label on DailyMed.